Evidence map›Paper›PMID 26344945›Full record

ArticleVaccines2015

The Potential Impact of Preventive HIV Vaccines in China: Results and Benefits of a Multi-Province Modeling Collaboration.

Thomas Harmon, Wei Guo, John Stover, Zunyou Wu, Joan Kaufman, Kammerle Schneider, Li Liu, Liao Feng, Bernard Schwartländer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Thomas HarmonInternational AIDS Vaccine Initiative, 125 Broad St., 9th Floor, New York, NY 10004, USA. tharmon@iavi.org.
Wei GuoChinese National Center for AIDS/STD Control and Prevention (NCAIDS), Beijing 102206, China. guowei@chinaaids.cn.
John StoverFutures Institute, Glastonbury, CT 06033, USA. Jstover@FuturesInstitute.org.
Zunyou WuChinese National Center for AIDS/STD Control and Prevention (NCAIDS), Beijing 102206, China. wuzunyou@chinaaids.cn.
Joan KaufmanColumbia University Global Centers, East Asia, Beijing 100080, China. jak2241@columbia.edu.
Kammerle SchneiderPATH, Seattle, WA 98121, USA. kschneider@path.org.
Li LiuCenter for Disease Control and Prevention of Sichuan Province, Chengdu 610041, China. liulir@163.com.
Liao FengCenter for Disease Control and Prevention of Sichuan Province, Chengdu 610041, China. fengliao1211@aliyun.com.
Bernard SchwartländerJoint United Nations Programme for HIV/AIDS (UNAIDS), Geneva CH-1211, Switzerland. schwartlanderb@wpro.who.int.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

China's commitment to implementing established and emerging HIV/AIDS prevention and control strategies has led to substantial gains in terms of access to antiretroviral treatment and prevention services, but the evolving and multifaceted HIV/AIDS epidemic in China highlights the challenges of maintaining that response. This study presents modeling results exploring the potential impact of HIV vaccines in the Chinese context at varying efficacy and coverage rates, while further exploring the potential implications of vaccination programs aimed at reaching populations at highest risk of HIV infection. A preventive HIV vaccine would add a powerful tool to China's response, even if not 100% efficacious or available to the full population.

Indexed as

ChinaHIV/AIDSmodelingpreventionresearchSichuanvaccines

Identifiers

PMID26344945
PMCPMC4494240

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.